Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study.
Simple Summary: There is limited Canadian real-world data that shows how palbociclib, a first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, is being used in Canadian women. Using health administrative data from Alberta, Cana...
| Publicado en: | Current Oncology Vol. 31; no. 2; pp. 81 - 93 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Feb2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191975506&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191975506 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Feb2026 vid: 31 iid: 2 pid: 97109 pub: MDPI artinfo: ui: 191975506 10.3390/curroncol33020081 191975506 ppf: 81 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study. aug: au: Rayson, Daniel Bertin, Jonathan Lemelin, Maxim Tong, Madeline Ng, Ryan Ding, Philip Cheung, Winson Y. Sharma, Arushi On, Phu Vinh Feugère, Guillaume Lupichuk, Sasha affil: Division of Medical Oncology, Dalhousie University, Halifax, NS B3H 2Y9, Canada sug: ab: Simple Summary: There is limited Canadian real-world data that shows how palbociclib, a first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, is being used in Canadian women. Using health administrative data from Alberta, Canada, this study examined the records of 472 female breast cancer patients who were inferred to have received palbociclib as first-line therapy and found that the median duration of treatment was 13.8 months and that the probability that these patients discontinued treatment within the first year was 45%. When patients receive palbociclib, they also receive an endocrine therapy in the form of an aromatase inhibitor (83% of patients in this study) or fulvestrant (14% of patients in this study). The median duration of treatment for patients receiving palbociclib with an aromatase inhibitor was 15.1 months, while the median duration of treatment for patients receiving palbociclib with fulvestrant was 7.9 months. Canadian real-world data (RWD) regarding palbociclib as a first-line therapy for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) is limited. The PALbociclib CANadian (PALCAN) study examined palbociclib utilization patterns as first-line treatment for HR+/HER2− MBC using Alberta health administrative data. The final PALCAN cohort included 472 female patients with a median age of 64 years and a median follow-up time of 22.8 months (IQR: 0.7–88.2). The median (95% CI) duration of treatment was 13.8 (12.7–15.1) months in the overall cohort (IQR: 5.6, 24.8 months), and the probability of treatment discontinuation within the first year was 45%. Aromatase inhibitors (AIs) and fulvestrant were the accompanying endocrine therapies (ETs) in 83% (N = 393) and 14% (N = 64) (15 with unknown accompanying therapy) of patients, respectively. The median duration of treatment for patients receiving an AI as an accompanying therapy was 15.1 (13.6–17.4) months and 7.9 months (5.8–12.6) for patients receiving fulvestrant, which may suggest endocrine resistance in the latter group. The PALCAN data provides insights into practice patterns and the effectiveness of palbociclib as a first-line therapy in female patients with HR+/HER2− breast cancer in the Canadian real-world setting. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|